Thus, with an unprecedented speed of RNA therapeutic development, we can establish a novel RNAi-based therapy targeting theTUG1/miR-122-5p/ALDOA/PKM axis for HCC treatment. This evidence concerns the gene PKM and hepatocellular carcinoma.